Ikena Oncology, Inc. (NASDAQ:IKNA) Short Interest Up 34.1% in February

Ikena Oncology, Inc. (NASDAQ:IKNA) was the recipient of a large increase in short interest in February. As of February 15th, there was short interest totalling 154,100 shares, an increase of 34.1% from the January 31st total of 114,900 shares. Based on an average trading volume of 226,700 shares, the short-interest ratio is currently 0.7 days. Currently, 1.1% of the company’s shares are sold short.

Hedge Funds Weigh In On Ikena Oncology

Institutional investors have recently bought and sold shares of the company. BML Capital Management LLC raised its holdings in Ikena Oncology by 395.8% during the 4th quarter. BML Capital Management LLC now owns 3,585,866 shares of the company’s stock valued at $5,881,000 after acquiring an additional 2,862,578 shares during the period. Gilead Sciences Inc. bought a new position in shares of Ikena Oncology in the fourth quarter worth $3,294,000. NEA Management Company LLC increased its holdings in shares of Ikena Oncology by 5.3% in the third quarter. NEA Management Company LLC now owns 600,063 shares of the company’s stock worth $1,038,000 after purchasing an additional 30,013 shares during the period. Peapod Lane Capital LLC bought a new position in shares of Ikena Oncology in the fourth quarter worth $833,000. Finally, Geode Capital Management LLC increased its holdings in shares of Ikena Oncology by 21.0% in the fourth quarter. Geode Capital Management LLC now owns 327,962 shares of the company’s stock worth $538,000 after purchasing an additional 56,936 shares during the period. Hedge funds and other institutional investors own 75.00% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have recently weighed in on the company. Wedbush reissued a “neutral” rating and issued a $2.00 price objective on shares of Ikena Oncology in a research report on Monday, December 23rd. HC Wainwright reaffirmed a “buy” rating and issued a $4.00 target price on shares of Ikena Oncology in a research report on Monday, November 11th.

Ikena Oncology Stock Down 3.7 %

Shares of NASDAQ IKNA opened at $1.29 on Tuesday. Ikena Oncology has a twelve month low of $1.22 and a twelve month high of $1.94. The stock’s 50 day moving average price is $1.50 and its 200-day moving average price is $1.63. The company has a market capitalization of $62.25 million, a PE ratio of -1.05 and a beta of 0.48.

Ikena Oncology Company Profile

Ikena Oncology, Inc operates as an oncology company that develops differentiated therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the United States. Its lead program is IK-930, an internally discovered, oral, TEAD1-selective, small molecule inhibitor of the Hippo pathway.